Thiamphenicol landed on the scene as a thoughtful answer to the risks and rewards of antibiotic use. Researchers looking to sidestep the substantial risks tied to chloramphenicol, especially issues like bone marrow suppression, searched for something with similar effectiveness but a lower chance of exceeding safe toxicity limits in humans and animals. Italian chemists at Farmitalia built on the framework of chloramphenicol in the late 1960s. Their tweaks produced thiamphenicol—an analog with a methyl-sulfonyl group in place of the nitro group. This change, though it sounds simple, managed to cut down on the risk profile, which made it stand out from its older cousin. Since then, veterinary practices and the human health sector in various regions have pulled thiamphenicol into their toolkits, not because it’s perfect, but because it spoke directly to the problem of balancing bacterial control and patient safety.
Thiamphenicol tells a story of adaptation. With roots in the amphenicol family, this antibiotic blocks bacterial protein synthesis, mainly by connecting to the 50S ribosomal subunit. Its spectrum covers both Gram-positive and Gram-negative bacteria, but it truly shines in veterinary settings—especially in the livestock and aquaculture sectors where certain pathogens threaten major economic interests. Some countries have allowed it for human use; others stick to animal applications only, often because of regulatory caution around even remote toxicity risks. The way thiamphenicol spread across public health systems reflects both its strengths and the tough calls regulators constantly face.
Thiamphenicol comes as a white to greyish powder, sparingly soluble in water but mixing well with solvents like acetone and ethanol. Its melting point sits between 169°C and 170°C, so it tolerates a fair amount of heat before breaking down. Unlike chloramphenicol, the absence of a nitro group reduces its tendency to form harmful metabolites after administration. The molecule’s formula (C12H15Cl2NO5S) explains the antibiotic’s resilience against many degrading forces in animal or environmental systems—a detail vitally important when dosing animals that contribute to the human food chain.
Strength and purity depend on the production process, but the technical grade often clocks in at 98% or better. Impurities must stay under strict limits, since even minuscule contamination can have ripple effects, especially in food-producing animals. Most suppliers mark packaging with batch numbers, expiration dates, storage instructions, and country-specific usage approvals. I’ve seen regulatory agencies such as the European Medicines Agency and the U.S. FDA pay particular attention to country of origin, impurity profiles, and potential residues, all areas where traceability trumps marketing claims. Trusted supply chains matter here more than fancy branding ever could.
Most commercial thiamphenicol comes via chemical synthesis that starts from D-threo-2-amino-1-(p-nitrophenyl)-1,3-propanediol, following a reaction path that swaps out the nitro group for a methyl-sulfonyl group while retaining the propanediol backbone. The process includes several steps: diazotization, sulfonylation, and hydrolysis, followed by careful crystallization and drying. Everything hangs on controlling temperature and reaction time, since errors here can raise impurity levels or kill yield. Process innovation continues, with certain pharma companies trying to lower solvent consumption or recycle byproducts to cut waste—a rare but welcome nod to sustainability.
Chemical tweaking gives thiamphenicol a life beyond its origins. Efforts grow every year to find derivatives with higher selectivity or specialized pharmacokinetics. Some research teams have tried attaching new groups to the backbone, aiming to push the molecule past resistant bacteria or alter its water solubility. Others played with prodrug formats, which release the active compound only after entering animal tissue. These modifications don’t just serve intellectual curiosity; pharmaceutical companies want clear advantages in bioavailability or reduced resistance, but most of these analogs remain experimental. Chemistry here doesn’t sit still, and the drive for new formulations to tackle stubborn infections keeps momentum alive.
Ask around veterinary supply shops and you’ll see thiamphenicol under names like Florfenicol, Althrocin, and Thiophenicol. Scientific circles might call it 4-Methylsulfonyl-dichloroacetamidophenyl-1,2-propanediol, but nobody outside of chemistry classes uses the mouthful. Brand names shift based on geography and company. This loose collection of labels sometimes confuses newcomers, especially given how the antibiotic moves differently across borders. That’s why medical professionals watch drug codes and batch numbers more than what’s printed on the front.
In clinical and farm settings, safety demands respect. Thiamphenicol avoids some of the worst risks of chloramphenicol—like aplastic anemia—yet no one pretends it’s risk-free. Staff handling raw powder or finished product wear gloves, masks, and lab coats. Many operations demand fume hoods for large-scale weighing or mixing, since dust inhalation can take a toll over time. Anyone administering the drug in aquaculture or livestock environments tracks withdrawal periods closely. Regulatory agencies test for residues with sharp eyes. On the flip side, countries without strong oversight have seen trouble: antibiotic resistance, accidental overdosing, and even smuggling. Funding proper education and monitoring has to rank high for anyone serious about safe use.
Thiamphenicol’s biggest impact shows up in animal health—fish farms treating columnaris disease, poultry operations fighting respiratory infections, and swine farms keeping E. coli under control. Some hospital settings outside Europe—especially in Asia and Latin America—rely on it for stubborn bacterial infections where alternatives have failed. Use in humans always comes with a warning label, reflecting years of debate among clinical pharmacists and toxicologists. The antibiotic sometimes pops up in research on multi-drug resistant pathogens, serving as a point of comparison for newer compounds, but animal agriculture remains its main domain. Anyone who has seen the devastation of a bacterial outbreak in livestock understands the value at stake—not as a silver bullet, but as a line of defense against collapse.
Innovation hasn’t ignored thiamphenicol, even as headline-grabbing drugs crowd the stage. Researchers keep exploring new salt forms, long-acting injectables, and oral solutions tailored to specific animal species. Pharmaceutical companies, driven by both regulatory needs and market demand, support bioequivalence studies and new residue detection systems. A steady stream of peer-reviewed articles discusses tweaks to the dosing schedule that push the drug’s benefits farther while minimizing exposure. The last decade’s focus on antimicrobial stewardship pushes labs to fine-tune protocols and restrict use, so thiamphenicol doesn’t join the ranks of lost antibiotics. Ongoing surveillance programs watch for resistance trends, comparing data from different countries to spot trouble early.
Those in toxicology know thiamphenicol fares better than many antibiotics but can’t afford to be taken lightly. Animal studies show dose-dependent bone marrow suppression at much higher rates than standard use, signaling the need for caution with extended therapies. Acute toxicity remains low in the usual host species, yet cases of hypersensitivity, gastrointestinal upset, and rare allergic reactions require prompt response. Human studies—where available—flag risks only in vulnerable populations. No one can ignore the risk of residues entering the food chain either; even low concentrations add up for populations eating meat, milk, and fish. Monitoring and transparent regulation do the heavy lifting in this arena, with both commercial and public health labs running regular residue checks in products destined for markets.
Antibiotic resistance isn’t slowing down, so thiamphenicol’s role keeps evolving. As emerging pathogens gain a foothold in intensive farming and wild fisheries, producers need tools that don’t push resistance to the brink. Thiamphenicol isn’t a silver bullet, but it gives veterinarians options outside of major antibiotics known to trigger cross-resistant strains. At the same time, pressure from regulators and consumers means the industry has to rethink how much, how often, and in what form antibiotics reach animal populations. Future research leans toward safer formulations, better targeted dosing, and environmental monitoring to close loopholes. As both a warning and a resource, thiamphenicol holds a mirror to how much society values balance between food safety and smart antibiotic use. If more attention goes to collaborative surveillance, responsible prescribing, and ongoing innovation, thiamphenicol stands a chance to contribute meaningfully for years to come.
Thiamphenicol doesn’t pop up much in clinics across North America or Western Europe, but step into a pharmacy in parts of Asia, South America, or Africa, and you’re likely to find it sitting right next to amoxicillin and doxycycline on the antibiotic shelf. This compound traces its roots to the same family as chloramphenicol, a medicine that once revolutionized the fight against typhoid and meningitis, but earned reputation risks due to bone marrow toxicity. Thiamphenicol offers most of the same bug-fighting punch, minus some of the stronger side effects.
Doctors in regions with resistant bacterial strains lean on thiamphenicol because it usually works where cheaper antibiotics fail. It targets a wide range of bacteria — ones that hit the chest, urinary tract, and even cause sexually transmitted infections. In my years volunteering at rural clinics, I noticed doctors grabbing thiamphenicol for infections like pneumonia or certain venereal diseases, especially in places where chloramphenicol triggered health scares. The world’s health authorities don’t throw new antibiotics at every mild infection, but when older options stop working, doctors need alternative choices.
Thiamphenicol doesn’t cause as many cases of aplastic anemia compared to its notorious cousin. That makes it a safer fallback, especially for people allergic to penicillin or those needing heavy-hitting antibiotics. Thiamphenicol also gets absorbed well when taken as a pill and doesn’t need complicated monitoring. I’ve seen firsthand how that matters in clinics far from major hospitals, where routine blood checks aren’t easy.
Thiamphenicol isn’t just reserved for people. Veterinarians use it to treat livestock and pets battling tough infections. Farmers count on it for cases of respiratory or digestive disease in pigs and cattle, when other drugs don’t cut it. With the global concern about drug residues in food, some countries keep tight controls on thiamphenicol use, but others rely on it for economic reasons.
Like any antibiotic, thiamphenicol can mess with gut bacteria and cause side effects such as nausea or diarrhea. There’s a small chance blood cell counts could still drop, especially with high doses or long-term use. In my experience, careful prescribing and short courses of therapy help dodge most trouble. Antibiotic resistance always lurks; that’s a lesson hammered home in both hospitals and public health lectures. Using the medicine wisely, not over-prescribing, and making sure patients finish their course help slow down resistance.
Affordable, safe antibiotics matter in places where more expensive drugs aren’t an option. Thiamphenicol stands out in those settings. Increased access should come with better doctor training and checks on pharmacies so people don’t just grab antibiotics at the first cough. Investment in diagnostic tools could help ensure thiamphenicol only goes out with a real infection, not for every fever. By pairing old medicines with responsible practices, healthcare workers can protect a treatment tool that helps millions where it’s needed most.
Thiamphenicol often ends up overlooked in talks about antibiotics, but folks in medicine know about its value. Doctors pick this medicine when patients face tough bacterial infections, especially in places where the more famous chloramphenicol may cause concern because of its notorious side effect—bone marrow suppression. Thiamphenicol comes with a lower risk of those blood-related problems and has good action against some difficult-to-treat germs.
Most of the time, this drug comes as a pill or capsule, but in some settings—think hospitals tackling serious infections—doctors use an injection. Kids get a syrup or oral suspension since swallowing pills isn’t easy for the younger ones. Thiamphenicol gives doctors some flexibility: there’s a solid route for daily outpatient needs, and a more direct line with an injection for emergencies or when people have trouble swallowing.
Doctors tailor the dose to the infection and the patient. With regular tablets, adults usually need to swallow them twice or three times a day. In my own years volunteering at clinics, the need to stick with a dosing schedule often caused more trouble than the medicine itself. Patients miss doses and that lets bacteria regroup and grow.
Those getting injections usually end up in the hospital, so nurses give doses straight into a vein or muscle. Injections don’t just work faster—they also sidestep problems like vomiting or bad absorption in the gut. Some places, especially in parts of South America and Asia, use Thiamphenicol as a front-line option for tough lung infections or even typhoid.
Not everyone has a pharmacy down the road with a shelf of options. In countries short on basic pills, doctors sometimes use animal-graded versions or order imports meant for another health system. That introduces questions about dose accuracy and purity. Patients who skip doses, split pills to make the box last, or take animal versions face higher odds for resistance and side effects.
In clinics with little oversight, antibiotics sometimes look less like a cure and more like a guessing game. One family I met in rural Peru got instructions from a traveling vendor—mix half of one big capsule with orange juice. Nobody knew if that was just the right amount or far too little. Kids under-dosed can drag infections out, and adults overdoing it risk other side effects, such as gut trouble or odd skin reactions.
Teaching folks about the reason behind precise dosing matters. Patients do better if clinics supply clear instructions and simple packaging. Government health systems could pitch in by making sure only human-approved drugs get dispensed, and doctors get reliable guidance to avoid fueling resistance. It’s better for everyone if antibiotics stay effective, so supporting clear routes for legal access and safe use isn’t just smart policy—it keeps communities safe in the long run.
Thiamphenicol doesn’t always top the charts like some newer pills, but in the hands of a trained health worker, with the right instructions and support, it holds its ground as a tool against infection. That staying power matters most where other options fall short.
People often look to antibiotics like thiamphenicol to clear up stubborn infections, especially in places where options are limited. Thiamphenicol’s strength lies in its ability to fight bacteria that don’t back down easily. Even with that muscle, it comes with side effects that call for attention. Nausea, vomiting, and stomach pain show up more often than others, leaving folks feeling drained and uncomfortable. Some notice diarrhea, while others lose their appetite. Skin rashes come up occasionally, a tip-off from the body that something is amiss.
Many patients share stories about headaches or dizziness, making daily routines harder. Gums might bleed or bruise easily, raising a flag. These symptoms feel minor at first, but ignoring them risks real trouble. Health professionals keep an eye on these tell-tale signs to catch problems before they spiral.
Thiamphenicol stands out as a safer sibling to chloramphenicol, yet its potential for suppressing bone marrow remains real. Doctors and pharmacists know blood counts can drop if thiamphenicol lingers in the system for long. Anemia, infections, and easy bruising point to this kind of trouble. Those already weakened by chronic illness or using several drugs together carry extra risk. There have been rare cases where white blood cells tank drastically, putting the immune system under strain. Blood tests help spot these changes early, much like checking oil in an engine before damage mounts.
Allergic reactions deserve mention too. Swelling in the face, breathing trouble, and a quickened heartbeat might signal a rare but strong allergy. Anyone feeling these symptoms should reach for medical help at once. Drug allergies can knock people off guard, though years of research highlight just how infrequent but serious they are.
Thiamphenicol often appears in livestock as well as clinics, and this broad use brings up questions about antibiotic resistance. Overuse in farming can breed stronger bugs, a threat that lingers in water, vegetables, and even hospital wards. Families who travel or work in healthcare see these changes firsthand, watching as once-simple infections turn into weeks-long battles.
Taking thiamphenicol for longer than needed adds to the risk. Doctors now work hard to match treatment length to infection type. They push for shorter courses, especially when blood counts start dropping. Pharmacists remind people to watch for symptoms and report back quickly.
People can lower the risks by sticking close to advice just as they would with a car mechanic or electrician. Ask questions about timing, possible interactions, and the best food or drink to pair with the medicine. Bringing up herbal supplements and all over-the-counter drugs leads to better outcomes because it gives doctors the whole story.
Hospitals and clinics benefit by running routine blood counts for those on long-term thiamphenicol. Quick action and regular check-ins catch side effects before they drag someone’s health down. Farmers and food producers step up by saying no to antibiotics in animal feed except when needed.
Smart use, not fear or avoidance, shapes a healthier relationship with antibiotics. Thiamphenicol serves as both a helpful tool and a reminder that medicines work best with respect and responsibility from everyone involved.
Thiamphenicol often enters the conversation as a substitute for chloramphenicol, especially in treating infections where other antibiotics fall short. Its profile seems attractive at first glance. Resistance builds more slowly, bone marrow effects rarely pop up, and dosing manages to stay convenient for the practitioner. Parents sometimes ask about it because it crops up in pediatric settings, or questions arise around possible use during pregnancy.
The reality is that thiamphenicol has a history in pediatrics, but only for specific infections when other drugs fall short. Like its cousin chloramphenicol, it can cross cell membranes easily and build up in tissues. That’s both a strength and a weakness. Blood disorders such as aplastic anemia, seen with chloramphenicol, remain rare with thiamphenicol, but the specter of gray baby syndrome—where a baby’s liver can’t handle the drug—remains. The risk runs higher in newborns and young infants. In older children, side effects drop off but still deserve a watchful eye.
Even with decades of use in parts of Asia and South America, doctors in the United States and Europe rarely reach for thiamphenicol. Infection-control protocols reserve it for situations where nothing else works, since safer alternatives exist. The World Health Organization puts emphasis on narrow-spectrum antibiotics for kids whenever possible, and thiamphenicol doesn’t land on the preferred list for most common infections.
Pregnant women face a different set of risks. Thiamphenicol crosses the placenta, which means the drug can reach the fetus. Animal studies don’t point to obvious birth defects, but high doses sometimes lead to growth problems, which sparks concern. Decisions about antibiotics during pregnancy usually rely on clear evidence of safety, a principle reinforced by organizations like the American College of Obstetricians and Gynecologists. Without strong proof that thiamphenicol delivers a benefit without increasing risk, it stays off most guidelines for pregnant women.
A pregnant woman fighting a severe infection naturally feels desperate for an answer. Still, doctors often step back at this point, weighing the consequences for both mother and child. Most turn to options such as penicillins, cephalosporins, or macrolides. Thiamphenicol’s track record doesn’t outweigh peace of mind when safer choices exist.
Some practitioners in certain regions hold onto thiamphenicol as a last resort. The World Health Organization and leading pediatric groups in high-resource settings stress antibiotics with well-established safety records. Families sometimes push for stronger medications, especially during tough illnesses, but the push for thiamphenicol rarely receives much support from professionals trained in evidence-based medicine.
One possible solution: more research focused on small children and pregnant women. Only proper trials bring the certainty needed for wider recommendations. Until those studies happen, doctors stick to what they know keeps risks low. Patient education emerges as a crucial task. Explaining drug safety in plain language lets families take an active role, alleviating worry and helping avoid unnecessary side effects.
Evidence guides the safest path—especially in vulnerable groups. Until thiamphenicol builds a stronger safety case, it lingers at the fringes of modern pediatric and obstetric care.
Thiamphenicol and Chloramphenicol both show up in medical stories as antibiotics born from similar roots. They seem close, but their differences can change the course of a diagnosis. I’ve seen people get confused by their almost twin-like chemistry, thinking they act exactly the same way in treatment. That's not the case. Each drug has its own set of strengths and concerns. Understanding these can make a real difference in patient care and public health decisions.
Chloramphenicol sprung up from Streptomyces venezuelae and was one of the earliest antibiotics that showed powerful effects against a wide range of bacteria. Thiamphenicol showed up a little later, bearing only a small chemical tweak—a methyl-sulfonyl group standing in for a nitro group. This small change seems simple, but it shapes the way the body handles these drugs. For example, Thiamphenicol gets processed more cleanly in the body, making it less toxic to bone marrow. Chloramphenicol, on the other hand, carries a well-known risk for aplastic anemia, sometimes fatal, which has rightfully scared off routine human use in many countries.
Sitting in hospital meetings, I’ve watched the worry that comes up around Chloramphenicol. Its risk of suppressing bone marrow doesn't just show up in numbers and research papers. It can mean the difference between running a safe infection-control program in a hospital versus dealing with a grim aftermath. Thiamphenicol doesn’t have that same reputation, as studies have shown a lower risk for dangerous effects on blood cells. This factor alone has led countries, especially in Asia and South America, to lean more on Thiamphenicol, sometimes using it more for human therapy, while Chloramphenicol sees life mostly in topical forms or animal medicine in places where prevention is needed for resistance control.
Any story about antibiotics must include resistance. For Chloramphenicol, bacteria have been building up walls for decades. Thiamphenicol isn’t immune to this issue either, though it tends to sidestep some of the resistance mechanisms due to its altered structure. Still, overuse or inappropriate use of either antibiotic just invites more trouble in the form of superbugs. Surveillance and stewardship programs step in here—doctors, pharmacists, and researchers have to check and re-check what works, what doesn’t, and how to keep these drugs as options for those rare but dangerous infections.
Practical choices in hospitals, clinics, and even farms drive demand for both drugs. In some countries, regulatory policies keep Chloramphenicol for the most desperate cases, treating typhoid fever or meningitis when nothing else breaks through. Thiamphenicol appears more accessible in veterinary care or in tackling some tough respiratory bugs. Not long ago, a vet explained he picked Thiamphenicol for treating respiratory outbreaks in animals because it caused fewer side effects compared to other drugs. That's direct experience guiding best practice—a lesson the wider medical community keeps learning as new challenges come up.
Doctors and pharmacists can lower side effect risks by picking the right drug for the right patient and paying close attention to emerging resistance. Hospitals can lock up use tighter, only letting these drugs out with infectious disease oversight. On the science side, researchers push for faster diagnostics, giving front-line staff real-time answers about which bacteria are in play, so these drugs keep their value for years to come. As patients, asking smart questions and being honest about symptoms help keep the balance in everyone’s favor. The legacy of both drugs depends on care—each step along the way.
| Names | |
| Preferred IUPAC name | D-threo-2,2-dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-methylsulfonylphenyl)ethyl]acetamide |
| Other names |
Thiamphenicolum Thiophenicol Tiamfenicol |
| Pronunciation | /θaɪˌæmˈfɛnɪkɒl/ |
| Preferred IUPAC name | D-threo-2-dichloroacetamido-1-(4-methylsulfonylphenyl)-1,3-propanediol |
| Other names |
Thiophenicol Thiamphenicolum Florfenicol precursor Tiamfenicol |
| Pronunciation | /θaɪˌæmˈfiːnɪkɒl/ |
| Identifiers | |
| CAS Number | 15318-45-3 |
| 3D model (JSmol) | `3D model (JSmol)` string of Thiamphenicol: ``` CCCC(=O)N(C)C1=CC=C(C=C1)S(=O)C2=NC(Cl)C(CO)O2 ``` This is the SMILES string representing the 3D structure for use in JSmol or similar viewers. |
| Beilstein Reference | 120697 |
| ChEBI | CHEBI:9517 |
| ChEMBL | CHEMBL1408 |
| ChemSpider | 122375 |
| DrugBank | DBN00765 |
| ECHA InfoCard | 100.086.619 |
| EC Number | 3.1.3.19 |
| Gmelin Reference | 83435 |
| KEGG | D08304 |
| MeSH | D013821 |
| PubChem CID | 27284 |
| RTECS number | YP9625000 |
| UNII | 1T38VZ42YN |
| UN number | UN2811 |
| CAS Number | 15318-45-3 |
| Beilstein Reference | 1207185 |
| ChEBI | CHEBI:9517 |
| ChEMBL | CHEMBL1436 |
| ChemSpider | 5469 |
| DrugBank | DBD00537 |
| ECHA InfoCard | 100.027.993 |
| EC Number | 1.1.1.235 |
| Gmelin Reference | 7544 |
| KEGG | D08215 |
| MeSH | D013926 |
| PubChem CID | 27274 |
| RTECS number | XN8575000 |
| UNII | 0003880043 |
| UN number | UN3249 |
| Properties | |
| Chemical formula | C12H15Cl2NO5S |
| Molar mass | 354.237 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.5 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -0.49 |
| Vapor pressure | <0.01 mm Hg (25°C) |
| Acidity (pKa) | 9.4 |
| Basicity (pKb) | 7.64 |
| Magnetic susceptibility (χ) | -72.0e-6 cm³/mol |
| Refractive index (nD) | 1.622 |
| Dipole moment | 1.61 D |
| Chemical formula | C12H15Cl2NO5S |
| Molar mass | 354.237 g/mol |
| Appearance | White or almost white crystalline powder |
| Odor | Odorless |
| Density | 1.72 g/cm³ |
| Solubility in water | Soluble |
| log P | -0.77 |
| Vapor pressure | <0.01 mmHg (25°C) |
| Acidity (pKa) | 10.41 |
| Basicity (pKb) | 5.56 |
| Magnetic susceptibility (χ) | -61.0×10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.612 |
| Dipole moment | 2.70 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 247.6 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -5271 kJ/mol |
| Std molar entropy (S⦵298) | Std molar entropy (S⦵298) of Thiamphenicol is 455 J·mol⁻¹·K⁻¹ |
| Std enthalpy of combustion (ΔcH⦵298) | -4995 kJ/mol |
| Pharmacology | |
| ATC code | J01BA01 |
| ATC code | J01BA01 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes eye and skin irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | Precautionary statements: P261, P264, P271, P272, P273, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P333+P313, P362+P364, P501 |
| Flash point | 106.6°C |
| Autoignition temperature | 150°C |
| Lethal dose or concentration | LD50 (oral, mouse): 1420 mg/kg |
| LD50 (median dose) | LD50 (median dose): Oral-rat LD50: 3000 mg/kg |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 30-50 mg/kg/day |
| IDLH (Immediate danger) | Not listed |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. May cause respiratory irritation. May cause damage to organs through prolonged or repeated exposure. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302, H315, H319, H335 |
| Precautionary statements | P261, P264, P271, P272, P273, P280, P302+P352, P305+P351+P338, P309+P311, P332+P313, P337+P313, P362+P364, P501 |
| Flash point | 82.9°C |
| Autoignition temperature | 140°C |
| Lethal dose or concentration | LD₅₀ (oral, rat): 2500 mg/kg |
| LD50 (median dose) | LD50 (median dose): Mouse oral > 14,000 mg/kg |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 30-60 mg/kg/day |
| Related compounds | |
| Related compounds |
Florfenicol Chloramphenicol |
| Related compounds |
Chloramphenicol Florfenicol |